LACHA-DOX has several exceptional features such as high stability, high tolerability, fast glutathione-responsive drug release, and superior selectivity toward CD44 that is overexpressed in several human hematological cancer cells as well as cancer stem cells. The gene discussed is CD44; the disease is hematopoietic and lymphoid cell neoplasm.